Safety and efficacy of high-dose clobetasol propionate 0.05% in cutaneous lichen planus.

Autor: Melin A; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Bouchereau S; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Guelimi R; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France.; EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France., Bergqvist C; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Condamina M; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Giraud-Kerleroux L; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Hirsch G; Department of Dermatology, Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France., Hua C; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Wolkenstein P; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Skayem C; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France., Le Cleach L; Department of Dermatology, AP-HP, Hôpital Henri Mondor, Faculté de Santé, Université Paris-Est, Créteil, France.; EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France.
Jazyk: angličtina
Zdroj: The Journal of dermatology [J Dermatol] 2023 Jun; Vol. 50 (6), pp. 810-813. Date of Electronic Publication: 2022 Dec 28.
DOI: 10.1111/1346-8138.16689
Abstrakt: Cutaneous lichen planus is a highly pruritic dermatosis with an unmet need in its management. The aim of this study was to evaluate the short-term effect and tolerance of high doses of clobetasol propionate 0.05% in cutaneous lichen planus. We conducted a single-center retrospective cohort study from 2017 to 2021. All adults treated with high-dose (>5 g/day) clobetasol propionate 0.05% for cutaneous lichen planus were included. Patients with less than 10% affected body surface area at initial presentation or who received concomitant systemic therapy were excluded. The primary endpoint was the rate of complete remission by week 16. Secondary endpoints included maximum daily and median cumulative doses, reduction in pruritus and occurrence of adverse events. Fifty-seven patients, 60% female, with a mean age of 48 years (min-max,18-83) were included. Cutaneous lichen planus had been present for a median duration of 2 months at initial presentation (min-max, 1-4) and involved a median body surface area of 27%. Pruritus was reported by 55/57 (96%) patients. At week 16, 41/57 (72%) patients had achieved complete remission without treatment modification, among whom 25/41 (61%) had achieved it at week 6. The median daily and cumulative doses were, respectively, 20 g/day (IQR, 10-20) and 560 g (IQR, 320-925). Three patients experienced mild adverse events. No statistical association was demonstrated between the duration of the disease before treatment initiation and clinical response. In conclusion, high-dose clobetasol propionate 0.05% seems to be an effective, well-tolerated, and easy-to-implement treatment for cutaneous lichen planus.
(© 2022 Japanese Dermatological Association.)
Databáze: MEDLINE
Externí odkaz: